Last reviewed · How we verify

Manufactured Anti-BCMA CAR-T cells

Thomas Martin, MD · Phase 1 active Biologic

Manufactured Anti-BCMA CAR-T cells is a Biologic drug developed by Thomas Martin, MD. It is currently in Phase 1 development. Also known as: Anti-BCMA CAR-T cells.

At a glance

Generic nameManufactured Anti-BCMA CAR-T cells
Also known asAnti-BCMA CAR-T cells
SponsorThomas Martin, MD
ModalityBiologic
PhasePhase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Manufactured Anti-BCMA CAR-T cells

What is Manufactured Anti-BCMA CAR-T cells?

Manufactured Anti-BCMA CAR-T cells is a Biologic drug developed by Thomas Martin, MD.

Who makes Manufactured Anti-BCMA CAR-T cells?

Manufactured Anti-BCMA CAR-T cells is developed by Thomas Martin, MD (see full Thomas Martin, MD pipeline at /company/thomas-martin-md).

Is Manufactured Anti-BCMA CAR-T cells also known as anything else?

Manufactured Anti-BCMA CAR-T cells is also known as Anti-BCMA CAR-T cells.

What development phase is Manufactured Anti-BCMA CAR-T cells in?

Manufactured Anti-BCMA CAR-T cells is in Phase 1.

Related